MULTIPLE SCLEROSIS, MITOCHONDRIA AND DIET THERAPY: AN OVERVIEW

2021 ◽  
pp. 132-135
Author(s):  
Joyeta Ghosh

Multiple sclerosis (MS) is dened as one chronic disease of central nervous system with neurodegenerative and inammatory components, where most of the patients shown a relapsingremitting course dened by the acute inception of focal neurologic decits and consistent focal inammatory changes visible on MRI. The causal factor of this complicated autoimmune and neurodegenerative disease is still unknown. Mitochondrial dysfunction is the key contributor to the neurodegenerative process of this disease. The current review signies the possible potential role of mitochondria in MS and the different dietary approach as a disease modier with the special emphasis on mitochondrial function and neurodegenerations.Research regarding therapeutic implementation of different diet in MS is advancing day by day; but currently remains with limited data. Few studies have been intended with meticulously collected observations, and the very few clinical trials that have been executed with insufcient sample size or length to adequately assess efcacy. More epidemiological and observational studies on dietary implementations were required

2014 ◽  
Vol 20 (11) ◽  
pp. 1439-1442 ◽  
Author(s):  
Marcin P Mycko ◽  
Howard L Weiner ◽  
Krzysztof W Selmaj

More than 80% of the human genome is biochemically active, whereas less than 3% of the genome encodes proteins. The emerging field of non-coding ribonucleic acids (RNAs) that are products of the genome, but do not program proteins, has revolutionized our understanding of cell biology. This was followed by a growing interest in the role of non-coding RNAs in the pathogenesis of human diseases, including multiple sclerosis (MS). In April 2013, a symposium in Warsaw, Poland, was the first meeting entirely dedicated to advances in the understanding of the roles of various subclasses of non-coding RNAs and showcased their involvement in autoimmune demyelination and MS. New mechanisms of action of small non-coding RNAs, as well as the advent of long non-coding RNAs were discussed, including the potential role of non-coding RNAs as MS biomarkers and their use for therapeutic intervention in MS.


2014 ◽  
Vol 36 (2) ◽  
pp. 105-113 ◽  
Author(s):  
Maryam Roozbeh ◽  
Hemn Mohammadpour ◽  
Gholamreza Azizi ◽  
Samira Ghobadzadeh ◽  
Abbas Mirshafiey

2015 ◽  
Vol 287 ◽  
pp. 80-87 ◽  
Author(s):  
Beatrice Macchi ◽  
Francesca Marino-Merlo ◽  
Ugo Nocentini ◽  
Valerio Pisani ◽  
Salvatore Cuzzocrea ◽  
...  

2014 ◽  
Vol 20 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Yuan Zhou ◽  
Steve Simpson ◽  
Adele F Holloway ◽  
Jac Charlesworth ◽  
Ingrid van der Mei ◽  
...  

It is now well established that both genetic and environmental factors contribute to and interact in the development of multiple sclerosis (MS). However, the currently described causal genetic variants do not explain the majority of the heritability of MS, resulting in ‘missing heritability’. Epigenetic mechanisms, which principally include DNA methylation, histone modifications and microRNA-mediated post-transcriptional gene silencing, may contribute a significant component of this missing heritability. As the development of MS is a dynamic process potentially starting with inflammation, then demyelination, remyelination and neurodegeneration, we have reviewed the dynamic epigenetic changes in these aspects of MS pathogenesis and describe how environmental risk factors may interact with epigenetic changes to manifest in disease.


2014 ◽  
Vol 10 (01) ◽  
pp. 48
Author(s):  
Dionysis Papadatos-Pastos ◽  
James Hall ◽  
Ruth Pettengell ◽  
Leslie R Bridges ◽  
Barry Newell ◽  
...  

We present a case of a 64-year-old man who was diagnosed with a primary anaplastic large cell lymphoma of the central nervous system (PCNSAL). He had received radical chemotherapy and radiotherapy for a non-small cell lung cancer (NSCLC) in the past. There is no known association between NSCLC and PCNSAL. We describe the diagnostic and therapeutic challenges associated with these rare intracranial lymphomas and highlight the potential role of newer biological agents in patients with anaplastic lymphoma kinase (ALK-1) positive PCNSAL.


Sign in / Sign up

Export Citation Format

Share Document